Sandbox ap: Difference between revisions

Jump to navigation Jump to search
Line 161: Line 161:
{{Family tree| | | | | | | | | | | | | S01 | | | | | | | | | | | | | | S02 | | | | | | | S01=Epitehelial injury|S02=Vascular injury}}
{{Family tree| | | | | | | | | | | | | S01 | | | | | | | | | | | | | | S02 | | | | | | | S01=Epitehelial injury|S02=Vascular injury}}
{{Family tree| | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |!| | | | | | | | }}
{{Family tree| | | | | | | | | | | | | |!| | | | | | R01 | | | | | | | R02 | | | | | | | R01=Mast cells|R02= LPA6, LPA2 and LPA4 receptors }}
{{Family tree| | | | | | | | | | | | | |!| | | | | | R01 | | | | | | | R02 | | | | | | | R01=Mast cells|R02= LPA6, LPA2, and LPA4 receptors }}
{{Family tree| | | | | | | | | | | | | |!| | | | | | |!| | | | | | |,|-|^|-|.| | | | | | }}
{{Family tree| | | | | | | | | | | | | |!| | | | | | |!| | | | | | |,|-|^|-|.| | | | | | }}
{{Family tree| | Q01 | | | | | | | | | Q02 | | | | | Q03 | | | | | Q04 | | Q05 | | | | | Q01=Decreased sFRP-1 (secreted frizzled-related protein 1)|Q02= Insulin-like growth factor (IGF) signalling|Q03=Transforming growth factor (TGF)-β|Q04= Reduced expression of angiogenic factors,<br>vascular endothelial growth factor (VEGF)|Q05=Elevation of angiostatic factors,<br>pigment epithelium-derived factor}}
{{Family tree| | Q01 | | | | | | | | | Q02 | | | | | Q03 | | | | | Q04 | | Q05 | | | | | Q01=Decreased sFRP-1 (secreted frizzled-related protein 1)|Q02= Insulin-like growth factor (IGF) signalling|Q03=Transforming growth factor (TGF)-β|Q04= Reduced expression of angiogenic factors,<br>vascular endothelial growth factor (VEGF)|Q05=Elevation of angiostatic factors,<br>pigment epithelium-derived factor}}

Revision as of 19:16, 2 March 2018

==Classification Gastritis

Gastritis Etiology Gasstritis synonyms
Non-atrophic
  • Helicobacter pylori
  • Other factors

Superficial Diffuse antral gastritis (DAG) Chronic antral gastritis (CAG) Interstitial - follicular Hypersecretory Type B*

Atrophic Autoimmune
  • Autoimmunity

Type A* Diffuse corporal Pernicious anemia-associated

Multifocal atrophic Helicobacter pylori Type B*, type AB*
Dietary Environmental
Environmental factors Metaplastic
Special form Chemical Chemical irritation Reactive
  • Bile
  • Reflux
  • NSAIDs
  • NSAID
  • Other agents
  • Type C*
Radiation Radiation injury

Risk assessment table

Scoring criteria for risk assessment*
Scoring system Score Risk
IMPROVEDD Score[1] Predicted % VTE risk through 42 days
0 0.4%
1 0.6%
2 0.8%
3 1.2%
4 1.6%
5-10 2.2%
Predicted % VTE risk through 77 days
0 0.5%
1 0.7%
2 1.0%
3 1.4%
4 1.9%
5-10 2.75
IMPROVE score[2] Predicted % VTE risk through 3 months
0 0.5%
1 1.0%
2 1.7%
3 3.1%
4 4%
5-8 11%
Padua Score[3] < 4 Low risk for VTE
≥ 4 High risk for VTE
Caprini score[4] 0-1 Low risk of VTE
2 Moderate of VTE
3-4 High risk of VTE
≥ 5 Highest risk for VTE

Pathophysiology of ILD

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epitehelial injury
 
 
 
 
 
 
 
 
 
 
 
 
 
Vascular injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mast cells
 
 
 
 
 
 
LPA6, LPA2, and LPA4 receptors
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Decreased sFRP-1 (secreted frizzled-related protein 1)
 
 
 
 
 
 
 
 
Insulin-like growth factor (IGF) signalling
 
 
 
 
Transforming growth factor (TGF)-β
 
 
 
 
Reduced expression of angiogenic factors,
vascular endothelial growth factor (VEGF)
 
Elevation of angiostatic factors,
pigment epithelium-derived factor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wnt/β-catenin signalling pathway
 
Tryptase
 
IGF-binding protein 3 (IGFBP-3)
 
 
 
IGF-binding protein 5 (IGFBP-5)
 
Upregulation of Egr-1 (early growth response protein 1)
 
 
 
 
 
 
Loss of endothelial barrier function
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dysregulation of repair
 
 
 
 
 
Regulates transforming growth factor (TGF)-β
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Induction of syndecan-2 (SDC2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activation,proliferation, and migration of fibroblast to the site of injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibroblasts
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altered PTEN (phosphatase and tensin homologue)/Akt axis
 
 
 
 
Acquire contractile stress fibres
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inactivates Fox (forkhead box) O3a
 
 
 
 
Protomyofibroblast,composed of cytoplasmic actins
 
Pleural mesothelial cells (PMCs)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Downregulation of cav-1 and Fas expression
 
 
 
 
De novo expression of α-SMA
 
TGF-β1-dependent mesothelial–mesenchymal transition
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibroblast resistant to apoptosis
 
 
 
 
 
 
Myofibroblasts
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Different ranges of contractions mediated by RhoA/Rho-associated kinase
 
 
Changes in intracellular calcium concentrations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibrocytes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lock step mechanism of cyclic and contractile events
 
 
 
 
 
 
 
 
 
T-helper cell type 2 on site of injury
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upregulation of C-X-C chemokine receptor type 4 (CXCR4)
on fibrocytes and its ligand
CXCL12 (stromal cell-derived factor 1)
 
 
 
 
 
Excess ECM production
 
 
 
 
 
Exerting traction force
 
 
 
 
 
 
 
 
 
Interleukin-13
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Migration of fibrocytes to the site of injury
 
 
 
 
 
Tissue remodelling
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alternate pathway activation of macrophages
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lung Fibrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

References

  1. . doi:10.1055/s-0037-160392910.1055/s-0037-1603929. Missing or empty |title= (help)
  2. Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH; et al. (2011). "Predictive and associative models to identify hospitalized medical patients at risk for VTE". Chest. 140 (3): 706–14. doi:10.1378/chest.10-1944. PMID 21436241.
  3. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M; et al. (2010). "A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score". J Thromb Haemost. 8 (11): 2450–7. doi:10.1111/j.1538-7836.2010.04044.x. PMID 20738765.
  4. Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F (1991). "Clinical assessment of venous thromboembolic risk in surgical patients". Semin Thromb Hemost. 17 Suppl 3: 304–12. PMID 1754886.